Full-Time

MSAT Training Specialist 2/3

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$75k - $95k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Bachelor’s degree in a life science discipline (e.g., Biology, Biotechnology) or equivalent experience.
  • 3-7 years of experience with mammalian cell culture manufacturing in a GMP environment.
  • Proven expertise as a Subject Matter Expert or Trainer in GMP cell culture manufacturing.
  • Extensive experience authoring and reviewing SOPs, batch records, and technical documents.
  • Advanced knowledge of aseptic techniques, cell counting, and GMP production methods.
  • Communication and presentation skills for diverse audiences.
  • Exceptional communication skills and attention to detail for training materials and records.
  • Ability to work independently and in a team in a dynamic setting.
  • Experience with cleanroom operations and gowning procedures preferred.
  • Knowledge of cell therapy manufacturing processes preferred.
Responsibilities
  • Develop and deliver training sessions on GMP cell culture manufacturing, cell counting, and aseptic techniques.
  • Design and implement innovative training modules and programs to enhance engagement and retention.
  • Collaborate with subject matter experts to align training materials with regulatory standards.
  • Mentor and coach manufacturing personnel, fostering a culture of continuous growth and strict GMP adherence.
  • Oversee the creation, review, and maintenance of SOPs, batch records, and technical documents for training and compliance.
  • Lead investigations, interviews, root cause analyses, and impact assessments for deviations, CAPAs, and change controls.
  • Manage the training lab, ensuring it is fully equipped, stocked, and prepared for all training activities.
  • Partner with Quality Assurance, Manufacturing, and Regulatory Affairs to integrate training with operational and compliance workflows.
  • Monitor and evaluate training effectiveness using feedback, performance metrics, and audits to drive continuous improvement.
  • Stay current with industry trends, regulatory changes, and best practices.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
  • Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
  • $318 million cash runway funds operations through Q4 2027 post-launch commercialization.

What critics are saying

  • FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
  • Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
  • EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.

What makes Capricor Therapeutics unique

  • First therapy delivering statistically significant upper limb function improvement in DMD.
  • Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
  • Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Capricor Therapeutics who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...